Amyloid PET and blood biomarker supplement to the Delirium Program Project
Amyloid PET and blood biomarker supplement to the Delirium Program Project
批准号:
10430721
负责人:
SHARON K. INOUYE
金额:
$22.73万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
已结题
起止时间:
2021-08-01 至 2023-05-31
关键词:
AchievementAgingAlzheimer&aposs DiseaseAlzheimer&aposs disease related dementiaAlzheimer’s disease biomarkerAmyloidAmyloid beta-42Biological AssayBiological MarkersBloodBrainCellsCerebrospinal FluidCerebrumCessation of lifeClassificationClinicalClinical TrialsCognitiveCognitive agingCytometryDataDeliriumDementiaDevelopmentDoctor of MedicineDoctor of PhilosophyEarly identificationElderlyElectroencephalographyElectrophysiology (science)EnrollmentEnsureFunctional disorderFutureGlial Fibrillary Acidic ProteinGoalsGrantHealth Care CostsHospitalizationImmuneImpaired cognitionImpairmentIncidenceIndividualInflammationInflammatoryKnowledgeLifeMagnetic Resonance ImagingMeasurementMeasuresMediatingMedicalModelingModificationMonitorNerve DegenerationNursing HomesOperative Surgical ProceduresOutcomeParentsParticipantPathway interactionsPatientsPatternPhenotypePhysiologyPlasmaPositron-Emission TomographyPostoperative PeriodPrevention strategyProbabilityProbability SamplesProteinsProteomicsRecording of previous eventsRiskRisk MarkerRoleSamplingScanningSeriesSeveritiesSpinal AnesthesiaSurgeonTestingTextValidationamyloid imagingbasecerebral atrophycognitive performancecohortcostcrosslinkdisabilityeffective interventionfollow-uphigh riskimaging biomarkerindexinginflammatory markerinnovationmagnetic resonance imaging biomarkermultimodalitynetwork dysfunctionneuroimagingneuroimaging markerneuropathologyneurophysiologynovelnovel markerpostoperative deliriumpre-clinicalpredictive modelingpredictive testpreferencepreventive interventionprogramsprospectivetau Proteinstau-1treatment response
中文摘要
摘要
英文摘要
Abstract
Delirium is a common, costly, life-threatening, and potentially preventable problem for older persons. The
development of delirium is considered to be a marker of brain vulnerability; however, its relationship to
dementia and Alzheimer’s disease and related dementias (AD/ADRD) remains unclear. In the parent Program
Project renewal grant, we are now conducting a series of 5 interlinked projects applying innovative approaches
to deepen our exploration of pathophysiologic pathways potentially contributing to delirium and its associated
cognitive decline. We are examining the role of amyloid markers in primary aims of Projects 1, 3, and 5, and in
cross-linking aims across all projects. In our original proposal, we proposed using cerebrospinal fluid (CSF)
biomarkers to quantify amyloid status in a subsample (n=128) of the SAGES I cohort, and in all of the new
SAGES II cohort (n=350-400); however, about 25-30% of the participants are either medically ineligible or will
not receive CSF sampling (due to their own or their surgeon’s preference). We will be completing SAGES II
cohort enrollment in the next year, and anticipate about 80-90 participants where CSF amyloid status will not
have been determined.
In this supplement, we request support for 2 Sub-Projects: (1) addition of 30 [F18] Florbetapir (“Amyloid”)
Positron Emission Tomography (PET) scans to measure amyloid status in SAGES II participants who did not
receive CSF sampling; (2) measurement of novel biomarkers for neurodegeneration (p-tau 181 and GFAP) in
stored plasma from the entire SAGES I cohort (n=560). This supplement will enhance the impact of the
Program Project in several ways. First, amyloid-PET will allow us to assure we can assess amyloid status for
most high-risk participants who do not receive CSF sampling, and to achieve the original aims. Second, PET
imaging allows abnormally elevated cerebral amyloid to be localized, which will offer opportunities to relate
amyloid imaging measures to the variety of MRI and electrophysiological measures we are obtaining. Third,
the biomarker assays would allow us to validate additional potential blood-based predictors of delirium,
delirium severity, and post-operative cognitive decline (aligned with our original aims), which would provide risk
markers to stratify future patients for clinical trials and to monitor response to treatment.
Thus, obtaining the additional scans and assays will ensure the achievement of our original aims and will
also magnify the overall impact of the Program Project, through modifications that are well-aligned with the
original aims. This supplement will truly bolster the Program Project, and allow it to achieve its goals of
advancing our understanding of delirium and its relationship to AD/ADRD, and ultimately, to develop more
effective strategies for prevention and treatment.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
NIDUS II: Advanced-Stage Development and Utilization of the NIDUS Research Infrastructure to Advance Interdisciplinary Aging Research in Delirium
-
批准号:10187721
-
项目类别:
-
资助金额:$79.46万
-
财政年份:2021
-
负责人:SHARON K. INOUYE
-
依托单位:
NIDUS II: Advanced-Stage Development and Utilization of the NIDUS Research Infrastructure to Advance Interdisciplinary Aging Research in Delirium
-
批准号:10561669
-
项目类别:
-
资助金额:$80.0万
-
财政年份:2021
-
负责人:SHARON K. INOUYE
-
依托单位:
NIDUS II: Advanced-Stage Development and Utilization of the NIDUS Research Infrastructure to Advance Interdisciplinary Aging Research in Delirium
-
批准号:10407605
-
项目类别:
-
资助金额:$80.0万
-
财政年份:2021
-
负责人:SHARON K. INOUYE
-
依托单位:
Delirium, Dementia, and the Vulnerable Brain: An Integrative Approach
-
批准号:10405113
-
项目类别:
-
资助金额:$271.63万
-
财政年份:2018
-
负责人:SHARON K. INOUYE
-
依托单位:
Social Isolation and Loneliness due to COVID-19: Effect on Cognitive, Physical, and Mental Health in Older Adults in the SAGES Study
-
批准号:10199108
-
项目类别:
-
资助金额:$52.07万
-
财政年份:2018
-
负责人:SHARON K. INOUYE
-
依托单位:
Delirium, Dementia, and the Vulnerable Brain: An Integrative Approach
-
批准号:10646679
-
项目类别:
-
资助金额:$15.67万
-
财政年份:2018
-
负责人:SHARON K. INOUYE
-
依托单位:
Development and Testing of a Framework of Social Determinants of Health for Delirium Tailored to Older Adults
-
批准号:10362053
-
项目类别:
-
资助金额:$15.67万
-
财政年份:2018
-
负责人:SHARON K. INOUYE
-
依托单位:
Administrative Core (Core A)
-
批准号:10405114
-
项目类别:
-
资助金额:$23.79万
-
财政年份:2018
-
负责人:SHARON K. INOUYE
-
依托单位:
Delirium, Alzheimer's Disease Biomarkers, and Long-Term Cognitive Decline
-
批准号:10405117
-
项目类别:
-
资助金额:$44.09万
-
财政年份:2018
-
负责人:SHARON K. INOUYE
-
依托单位:
Development and Validation of a Delirium Severity Toolkit
-
批准号:9520730
-
项目类别:
-
资助金额:$16.97万
-
财政年份:2017
-
负责人:SHARON K. INOUYE
-
依托单位:
Supplement to Network for Investigation of Delirium across the U.S (NIDUS)
-
批准号:9933609
-
项目类别:
-
资助金额:$24.23万
-
财政年份:2016
-
负责人:SHARON K. INOUYE
-
依托单位:
Network for Investigation of Delirium across the U.S. (NIDUS)
-
批准号:9922845
-
项目类别:
-
资助金额:$73.01万
-
财政年份:2016
-
负责人:SHARON K. INOUYE
-
依托单位:
Network for Investigation of Delirium across the U.S. (NIDUS)
-
批准号:9353283
-
项目类别:
-
资助金额:$74.94万
-
财政年份:2016
-
负责人:SHARON K. INOUYE
-
依托单位:
Network for Investigation of Delirium across the U.S. (NIDUS)
-
批准号:9202052
-
项目类别:
-
资助金额:$74.94万
-
财政年份:2016
-
负责人:SHARON K. INOUYE
-
依托单位:
BASILÃÂÃÂÃÂÃÂ Better Assessment of Illness: Delirium Severity Measures for Persons with and without Dementia
-
批准号:10417237
-
项目类别:
-
资助金额:$78.28万
-
财政年份:2014
-
负责人:SHARON K. INOUYE
-
依托单位:
Development and Validation of a Delirium Severity Toolkit
-
批准号:8870268
-
项目类别:
-
资助金额:$66.33万
-
财政年份:2014
-
负责人:SHARON K. INOUYE
-
依托单位:
BASIL - Better Assessment of Illness: Delirium Severity Measures for Persons with and without Dementia
-
批准号:10263174
-
项目类别:
-
资助金额:$78.51万
-
财政年份:2014
-
负责人:SHARON K. INOUYE
-
依托单位:
Development and Validation of a Delirium Severity Toolkit
-
批准号:8630029
-
项目类别:
-
资助金额:$66.51万
-
财政年份:2014
-
负责人:SHARON K. INOUYE
-
依托单位:
Development and Validation of a Delirium Severity Toolkit
-
批准号:9022384
-
项目类别:
-
资助金额:$68.18万
-
财政年份:2014
-
负责人:SHARON K. INOUYE
-
依托单位:
BASILÃÂÃÂÃÂÃÂ Better Assessment of Illness: Delirium Severity Measures for Persons with and without Dementia
-
批准号:10632025
-
项目类别:
-
资助金额:$72.8万
-
财政年份:2014
-
负责人:SHARON K. INOUYE
-
依托单位:
海外基金